Neurontin sales came in at $2.7 billion last year–with off-label prescriptions accounting for an estimated 90%. But Pfizer is paying dearly for those sales. Last month its Warner-Lambert division agreed to plead guilty and pay $430 million to resolve civil and criminal charges stemming from the fraudulent sales tactics. Under a federal whistle-blower law, Franklin earned a $26.6 million share of the settlement. Pfizer, meanwhile, says it never saw the kinds of practices that Warner-Lambert engaged in from its own sales force. "Pfizer's approach is proactive," says a company spokesman. "We've got good products and want to promote them in the appropriate ways."